This week, Model Medicines was selected to join the BARDA VANGUARD Program, a forward-looking initiative aimed at accelerating innovative technologies that can strengthen the United States’ ability to prevent and respond to public health emergencies.

The Biomedical Advanced Research and Development Authority (BARDA), under the U.S. Department of Health and Human Services (HHS), leads this program through its Division of Research, Innovation, and Ventures (DRIVe). VANGUARD functions as BARDA’s Enabling Technologies Hub and is operated in partnership with BioTools Innovator. The program identifies and supports transformative platforms in drug discovery, biomanufacturing, and clinical coordination. Model Medicines is proud to be one of only ten companies selected for VANGUARD.

This selection is more than symbolic; it aligns us with a mission to advance national health security. Our work is centered on developing therapeutics that can help mitigate future biological threats.

What This Means

Participation in VANGUARD provides Model Medicines with direct access to BARDA’s ecosystem, which includes regulatory, scientific, and operational expertise essential for rapid therapeutic development.

With BARDA's collaboration, we will:

• Expand our GALILEO™ platform, an AI-driven system that accelerates the discovery of antiviral agents

• Advance MDL-001 and our broader antiviral library, including oral broad-spectrum candidates targeting conserved viral polymerase structures, including the RdRp Thumb-1 allosteric site

• Collaborate with national agencies to ensure our therapeutics are stockpile-ready and deployable during early-stage outbreaks
  
  

Why It Matters

Robust pandemic response requires next-generation platforms that are both rapid and scalable.

To date, GALILEO™ has computationally generated over 192 candidate compounds, with 67 already demonstrating validation in preclinical disease models. Notably, Model Medicines is the only AI-native drug discovery company operating across a chemical search space of 53 trillion molecules, a scale that significantly expands the likelihood of finding effective, cross-pathogen treatments.

BARDA’s support enables us to apply these capabilities directly to the mission of protecting the U.S. from the next wave of biological threats.

Model Medicines will initiate formal engagement with BARDA and the other VANGUARD cohort members later this month. Together, we aim to:

Develop countermeasures that are effective across pathogens, fast to deploy, and scalable for nationwide use.

We are honored to be part of this initiative and remain committed to advancing therapeutic innovation that supports national health preparedness.